Athena Countouriotis

2.5k total citations · 1 hit paper
21 papers, 1.9k citations indexed

About

Athena Countouriotis is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Athena Countouriotis has authored 21 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 15 papers in Hematology and 11 papers in Rheumatology. Recurrent topics in Athena Countouriotis's work include Chronic Lymphocytic Leukemia Research (15 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Eosinophilic Disorders and Syndromes (11 papers). Athena Countouriotis is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Eosinophilic Disorders and Syndromes (11 papers). Athena Countouriotis collaborates with scholars based in United States, Italy and France. Athena Countouriotis's co-authors include Hagop M. Kantarjian, Carlo Gambacorti‐Passerini, Jörge E. Cortes, Tim H. Brümmendorf, Michele Baccarani, Timothy P. Hughes, Neil P. Shah, Dong‐Wook Kim, Karı̈n Gogat and Andreas Hochhaus and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Athena Countouriotis

20 papers receiving 1.9k citations

Hit Papers

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phas... 2012 2026 2016 2021 2012 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
    2012 344 citations Jörge E. Cortes, Dong‐Wook Kim et al. Journal of Clinical Oncology profile →

Peers

Athena Countouriotis
Albert Hoenekopp Switzerland
Concepción Boqué Spain
Beatriz Moiraghi Argentina
Phuong Dang Australia
Philipp D. le Coutre Germany
M. Brigid Bradley‐Garelik United States
Philippe Rousselot France
Anna Turkina Russia
Ron Paquette United States
Franck E. Nicolini France
Albert Hoenekopp Switzerland
Athena Countouriotis
Citations per year, relative to Athena Countouriotis Athena Countouriotis (= 1×) peers Albert Hoenekopp

Countries citing papers authored by Athena Countouriotis

Since Specialization
Citations

This map shows the geographic impact of Athena Countouriotis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Athena Countouriotis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Athena Countouriotis more than expected).

Fields of papers citing papers by Athena Countouriotis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Athena Countouriotis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Athena Countouriotis. The network helps show where Athena Countouriotis may publish in the future.

Co-authorship network of co-authors of Athena Countouriotis

This figure shows the co-authorship network connecting the top 25 collaborators of Athena Countouriotis. A scholar is included among the top collaborators of Athena Countouriotis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Athena Countouriotis. Athena Countouriotis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brümmendorf, Tim H., Jörge E. Cortes, Cármino Antônio De Souza, et al.. (2014). Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trial. British Journal of Haematology. 168(1). 69–81. 148 indexed citations
2.
Cortes, Jörge E., Dong‐Wook Kim, Hagop M. Kantarjian, et al.. (2012). Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. Journal of Clinical Oncology. 30(28). 3486–3492. 344 indexed citations breakdown →
3.
Gambacorti‐Passerini, Carlo, Jeffrey H. Lipton, Luis Felipe Casado, et al.. (2012). BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up.. Journal of Clinical Oncology. 30(15_suppl). 6512–6512. 4 indexed citations
4.
Starling, Naureen, David Cunningham, Ian Chau, et al.. (2011). A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Annals of Oncology. 23(1). 119–127. 21 indexed citations
5.
Cortes, Jörge E., François Guilhot, Ladan Duvillié, et al.. (2011). Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia – BELA Trial: 24-Month Follow-up. Blood. 118(21). 455–455. 15 indexed citations
6.
Gambacorti‐Passerini, Carlo, et al.. (2011). Safety and Management of Toxicities in the BELA Trial of Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Blood. 118(21). 1685–1685. 2 indexed citations
7.
8.
Gambacorti‐Passerini, Carlo, Jörge E. Cortes, Hagop M. Kantarjian, et al.. (2011). Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up.. Journal of Clinical Oncology. 29(15_suppl). 6509–6509. 14 indexed citations
9.
Boven, Epie, Christophe Massard, Jean‐Pierre Armand, et al.. (2010). A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. British Journal of Cancer. 103(7). 993–1000. 18 indexed citations
10.
Hecht, J. Randolph, T. Yoshino, Edith P. Mitchell, et al.. (2010). A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results.. Journal of Clinical Oncology. 28(15_suppl). 3532–3532. 8 indexed citations
11.
Hochhaus, Andreas, Michele Baccarani, Michael W. Deininger, et al.. (2008). Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 22(6). 1200–1206. 271 indexed citations
12.
Kantarjian, Hagop, Ricardo Pasqüini, Nelson Hamerschlak, et al.. (2007). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 109(12). 5143–5150. 277 indexed citations
13.
14.
15.
Zwaan, C. Michel, Monique L. den Boer, Berna Beverloo, et al.. (2006). Dasatinib (SPRYCEL®) in Children and Adolescents with Relapsed or Refractory Leukemia: Preliminary Results of the CA180018 Phase I/II Study.. Blood. 108(11). 2162–2162. 2 indexed citations
16.
Hochhaus, Andreas, Hagop M. Kantarjian, Michele Baccarani, et al.. (2006). Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109(6). 2303–2309. 445 indexed citations
17.
Hochhaus, Andreas, Hagop M. Kantarjian, Michele Baccarani, et al.. (2006). Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 ’START-C’ Study. Journal of Clinical Oncology. 24(18_suppl). 6508–6508. 20 indexed citations
18.
DiPetrillo, Thomas A., Paul Akerman, Tony Ng, et al.. (2005). Paclitaxel poliglumex (PPX) and concurrent radiation for treatment of patients with esophageal or gastric cancer: A dose-ranging study. Journal of Clinical Oncology. 23(16_suppl). 4065–4065. 3 indexed citations
19.
Cheng, Jerry C., et al.. (2003). Transcriptional Regulators and Myelopoiesis: The Role of Serum Response Factor and CREB as Targets of Cytokine Signaling. Stem Cells. 21(2). 123–130. 20 indexed citations
20.
Countouriotis, Athena, Theodore B. Moore, & Kathleen M. Sakamoto. (2002). Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies. Stem Cells. 20(3). 215–229. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Albert Hoenekopp Breakdown of academic impact, for papers by Concepción Boqué Breakdown of academic impact, for papers by Beatriz Moiraghi Breakdown of academic impact, for papers by Phuong Dang Breakdown of academic impact, for papers by Philipp D. le Coutre Breakdown of academic impact, for papers by M. Brigid Bradley‐Garelik Breakdown of academic impact, for papers by Philippe Rousselot Breakdown of academic impact, for papers by Anna Turkina Breakdown of academic impact, for papers by Ron Paquette Breakdown of academic impact, for papers by Franck E. Nicolini
Rankless by CCL
2026